Analysts expect Cadrenal Therapeutics, Inc. to report revenue of 0.00 for Q3 26, against a range of 0.00 to 0.00. The most recent reported quarter, Q2 26, came in at 0.00.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - |
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analysts expect Cadrenal Therapeutics, Inc. to report earnings per share of -1.07 for Q3 26, against a range of -1.17 to -0.97. The most recent reported quarter, Q2 26, came in at -1.14, a 23.5% beat against the -1.49 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -2.18 | -2.55 | -2.09 | -1.87 | -1.31 | -1.37 | -1.04 | -1.14 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -1.95 | -1.64 | -2.11 | -1.62 | -1.36 | -1.02 | -1.44 | -1.36 | -0.97 | -0.99 | -0.88 | -0.81 | -0.59 | -0.62 | -0.59 | -0.68 | ||||||||||
| Low Estimate | -2.17 | -1.96 | -2.39 | -1.82 | -1.66 | -1.20 | -1.68 | -1.62 | -1.17 | -1.13 | -1.00 | -0.87 | -0.65 | -0.66 | -0.69 | -0.72 | ||||||||||
| Consensus Estimate | -2.06 | -1.80 | -2.25 | -1.72 | -1.51 | -1.11 | -1.56 | -1.49 | -1.07 | -1.06 | -0.94 | -0.84 | -0.62 | -0.64 | -0.64 | -0.70 |